Land: Kanada
Sprache: Englisch
Quelle: Health Canada
LAMIVUDINE
JAMP PHARMA CORPORATION
J05AF05
LAMIVUDINE
300MG
TABLET
LAMIVUDINE 300MG
ORAL
100/1000
Prescription
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0128157005; AHFS:
APPROVED
2020-10-27
_JAMP Lamivudine Page 1 of 45 _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR JAMP LAMIVUDINE Lamivudine Tablets Tablets, 150 mg and 300 mg, oral USP Antiretroviral Agent JAMP Pharma Corporation 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: October 27, 2020 Date of Revision: November 15, 2022 _Submission Control No:_ 265182 _JAMP Lamivudine Page 2 of 45 _ _ _ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 11/2022 7 WARNINGS AND PRECAUTIONS, General 11/2022 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS ...................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 4 1 INDICATIONS............................................................................................................. 4 1.1 Pediatrics ..................................................................................................... 4 1.2 Geriatrics ...................................................................................................... 4 2 CONTRAINDICATIONS............................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX......................................................... 4 4 DOSAGE AND ADMINISTRATION ............................................................................ 5 4.1 Dosing Considerations .................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ................................................ 5 4.3 Missed Dose................................................................................................. 6 5 OVERDOSAGE .................................................................................................... Lesen Sie das vollständige Dokument